SCOPUS 정보 검색 플랫폼

New England Journal of Medicine

Volumn 371, Issue 3, 2014, Pages 273-274

Changes in the treatment landscape for chronic lymphoid leukemia

(1) Foà, Robin a

a SAPIENZA UNIVERSITY OF ROME (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; IBRUTINIB; IDELALISIB; OFATUMUMAB;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; HUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PYRAZOLES; PYRIMIDINES;

EID: 84904266704 PISSN: 00284793 EISSN: 15334406 Source Type: Journal
DOI: 10.1056/NEJMe1405766 Document Type: Editorial

Times cited : (9)

References (7)

1
- 84879748062
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
- Erratum, N Engl J Med 2014;370:786
- Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42. [Erratum, N Engl J Med 2014;370:786.]
- (2013) N Engl J Med , vol.369 , pp. 32-42
- Byrd, J.C.¹ Furman, R.R.² Coutre, S.E.³

2
- 84904252369
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
- Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-23.
- (2014) N Engl J Med , vol.371 , pp. 213-223
- Byrd, J.C.¹ Brown, J.R.² O'Brien, S.³

3
- 84896692766
- Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
- Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997-1007.
- (2014) N Engl J Med , vol.370 , pp. 997-1007
- Furman, R.R.¹ Sharman, J.P.² Coutre, S.E.³

4
- 84899087266
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014;123:2139-47.
- (2014) Blood , vol.123 , pp. 2139-2147
- Rossi, D.¹ Khiabanian, H.² Spina, V.³

5
- 84891373281
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial
- O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:48-58.
- (2014) Lancet Oncol , vol.15 , pp. 48-58
- O'Brien, S.¹ Furman, R.R.² Coutre, S.E.³

6
- 84902183019
- Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
- Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286-94.
- (2014) N Engl J Med , vol.370 , pp. 2286-2294
- Woyach, J.A.¹ Furman, R.R.² Liu, T.M.³

7
- 84900338667
- Treating hepatitis C in lower-income countries
- Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med 2014;370:1869-71.
- (2014) N Engl J Med , vol.370 , pp. 1869-1871
- Jayasekera, C.R.¹ Barry, M.² Roberts, L.R.³ Nguyen, M.H.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.